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Abstract 
 
Improved patient care coordination is critical for achieving better health outcome measures at 
reduced cost. Better integration of primary and secondary care in chronic illness care and 
utilizing the advantages of better collaboration between general practitioners and specialists may 
support these conflicting goals. Assessing patient care coordination at system level is, however, 
as challenging as achieving it. Based on prescription data from a private data vendor company, 
we develop a provider-level care coordination measure to assess the function of primary care at 
system level. We aim to provide empirical evidence for the possible impact of patient care 
coordination in chronic illness care—we investigate whether the type of collaborative 
relationship general practitioners have built up with specialists is associated with prescription 
drug costs. To our knowledge, no large-scale quantitative study has ever investigated this 
association. We find that prescription drug costs for patients treated by general practitioners who 
build up strong collaborative relationships with specialists are significantly lower than for 
patients treated by general practitioners characterized by fragmented collaborative structures. If 
future system-level studies in other settings confirm that total healthcare costs are indeed lower 
for patients treated in strong collaborative structures, then healthcare strategists need to advocate 
a healthcare system with lower care fragmentation on the interface of primary and secondary 
care. Regulating access to secondary care might result in significant cost savings through 
improved care coordination. 
 
JEL codes: C12, H51, I18 
 
Keywords: chronic illness care, care coordination, primary care, secondary care, administrative 
data, prescription drug costs 
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Introduction 
 
All over the world, governments face pressures of health care budget reductions while aiming at 
maintaining or even improving the level of service.  One way to achieve these conflicting goals 
may be through better integration of primary and secondary care in chronic illness care and 
utilizing the advantages of better collaboration between general practitioners and specialists. This 
integration is most frequently equated with shared care in the UK, managed care in the US, 
transmural care in the Netherlands, and other widely recognized formulations such as 
collaborative care, comprehensive care and disease management (Kodner 2002). 
 
Professional collaboration between general practitioners and specialists is one critical element of 
this integration. Professional collaboration reflects the extent to which general practitioners and 
specialists work together to achieve optimal outcomes for a given patient. Collaborative 
relationships in chronic illness care create opportunities for direct communication and 
information sharing that may lower barriers to care coordination.  
 
Empirical evidence suggests that the level of care coordination is positively related to clinical 
performance and outcomes (Bosch et al. 2009, Lemieux-Charles and McGuire 2006). Previous 
care coordination measures are, however, limited in their practical utility nowadays, because they 
involve time and cost intensive surveys that does not allow assessing the efficiency of health care 
systems on a large scale (Bynum and Ross 2013, Schulz et al. 2013). In the past, system-level 
care coordination has been impossible to measure. Recent availability of administrative data 
enabled researchers to develop new measures of care coordination applicable to system-level 
(Barnett et al. 2012, Pham et al. 2009, Pollack et al. 2013, Uddin et al. 2011). This new measure 
of care coordination relies on the number of shared patients, and assumes that the higher the 
number of shared patients, the higher the probability of developing collaborative relationships is. 
The measure has been validated for predicting the existence of collaborative relationships among 
doctors by Barnett et al. (2011). This novel measure focuses on ties in which the number of 
shared patients are high—provider-level care coordination measure has not been developed yet. 
This study fills this gap—the care coordination measure developed here has the general 
practitioners as providers in its focus acknowledging their role as gatekeepers and patient care 
coordinators. 
 
Assessing system level patient care coordination is as challenging as achieving it. This paper 
takes a leap forward in providing empirical evidence for the possible impact of patient care 
coordination—we investigate whether the type of collaborative relationship general practitioners 
have built up with specialists is associated with prescription drug costs. No large-scale 
quantitative study has ever investigated this association. Previous research either did not develop 
a system-level care coordination measure (Bosch et al. 2009, Lemieux-Charles and McGuire 
2006), or did not perform a provider-level analysis (Barnett et al. 2012, Pollack et al. 2013, Uddin 
et al. 2011). Moreover, to the authors’ knowledge, this analysis shall be considered as the first 
attempt to measure system-level care coordination in Europe, and the second one to assess a 
healthcare system with universal coverage (Uddin et al. 2011). 
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Methods 
 
The Hungarian healthcare system is primarily publicly funded, through taxation. Its universal 
health coverage sets minimum standards and aims to extend access as widely as possible. Patients 
are free to choose their general practitioners, who act as gatekeepers for the secondary and 
tertiary care provided by specialists. The care of patients with chronic conditions is shared 
between general practitioners and specialists. In shared care, general practitioners act as first 
points of contact, for patients, and as gatekeepers, for secondary care, whereas specialists test, 
diagnose, and treat patients. When specialists initiate therapies with specialist medication, usually 
of high cost, general practitioners have to prescribe that medication for a time, usually for one 
year. To obtain prescribed medication, patients have to visit their general practitioners monthly, 
allowing general practitioners to filter out—and refer back to specialists—cases where the health 
status had worsened under treatment. General practitioners channel patients to healthcare 
providers designated by National Health Insurance Fund of Hungary as nearest to either patient 
or general practitioner. However, general practitioners can refer patients to any outpatient 
services in Hungary, provided that patients make such requests on referral. 
 
We use prescription data for the years 2010-11 available from Doktorinfo Ltd, a health data 
collection and information services company based in Hungary. Twenty per cent of general 
practitioners practicing in Hungary feeds real-time prescription data into this database 
voluntarily—they are representative of the entire Hungarian general practitioner population in 
both age and location (defined by region and population size). General practitioners are 
compensated for providing information such as general practitioner identification number; 
prescription date; prescribed drug characteristics; International Classification of Diseases (ICD) 
codes; prescribed drug subsidy; patient characteristics (age and gender); and, since January 2009, 
for patients whose care is shared, identification number of the therapy-initiating specialist. The 
identification numbers of general practitioners and specialists enable the detection of 
collaborative relationships between prescribing general practitioners and therapy-initiating 
specialists. 
 
In this study, we focus on diabetic patients aged over 40 whose care is shared between general 
practitioners and specialists. Diabetic patients are defined as patients who received at least one 
specialist drug from the A10 ‘drugs used in diabetes’ subgroup of the Anatomical Therapeutic 
Chemical (ATC) Classification System—for example, insulin or an oral antidiabetic agent. 
 
The formal collaboration between general practitioners and specialists is materialized in referral 
and prescribing of special medications. Similar to the recent studies (Landon et al. 2012; Pham et 
al. 2009; Pollack et al. 2013; Uddin et al. 2011), collaborative relationship between two doctors 
exists if they care for at least one patient together. This information is readily and unambiguously 
available from the prescription data, where the identification numbers of prescribing general 
practitioners and therapy-initiating specialists both appear on prescriptions.  
 
The structure of collaborative relationships between general practitioners and specialists depends 
on both the number of specialists with whom general practitioners coordinate care and patient 
distribution across specialists. General practitioners channeling the majority of their patients to a 
few specialists build up strong, collaborative relationship with specialists, whereas general 
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practitioners channeling their patients to many specialists build up weak, fragmented 
collaborative ties.  
 
The structure of collaborative relationships between general practitioners and specialists is 
measured by the Herfindahl-Hirschman Index (HHI), a widely used concentration measure in 
industrial organization—the sum of the squares of the proportion of general practitioner’s 
patients shared with specialists (Rhoades 1993). The higher the index (it ranges from a very small 
number close to zero to 10,000 in case of a monopoly or 100% share), the more concentrated the 
collaborative structure of general practitioners, which implies stronger collaborative relationships 
among doctors. Figure 1, based on the sample data, shows examples for general practitioner–
specialist collaborative structures. The number assigned to each link indicates the number of 
patients treated in that general practitioner–specialist connection, whereas the percentages 
indicate the proportion of general practitioner’s patients treated in that general practitioner–
specialist connection. 
 
Figure 1 Strong vs fragmented collaborative structures 
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General practitioners build up strong collaborative relationship with specialists, if the HHI is in 
the uppermost decile; if HHI is in the lowest decile then general practitioners have weak, 
fragmented ties with specialists. General practitioners with strong collaborative ties may be 
strongly tied to more than one specialist. In this particular sample, general practitioners with a 
HHI higher than 6,258 qualify for strong collaborative relationship with specialists; whereas 
general practitioners with a HHI smaller than 1,743 qualify for weak, fragmented relationships. 
In additional sensitivity analyses we carried out, general practitioners with strong collaborative 
relationships were defined as general practitioners with a HHI in the top quintile/tertile, and 
general practitioners with weak, fragmented relationships as general practitioners with a HHI in 
the bottom quintile/tertile. 
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In a bivariate analysis, we first test whether the type of collaborative structure (strong versus 
fragmented) is associated with prescription drug costs. The skewed distribution of the 
collaborative relationship measure suggests a decile-based categorization. Prescription drug costs 
are measured as the sum of the retail prices for drugs prescribed by general practitioners—they 
include the amount paid by patient as well as any drug subsidy. Private and public 
pharmaceutical expenditure are thus considered jointly to assess the total cost to society. The cost 
implications of strong versus fragmented collaborative structures are evaluated using t-tests, 
considered significant if the p-value is less than 0.05. Sensitivity analyses are also carried out for 
the alternative definitions of strong and fragmented collaborative structures. 
 
In a multivariate regression analysis, potentially confounding variables are controlled for—the 
variation in prescription drug costs across the patient lists of general practitioners is explained by 
the type of collaborative structure and potentially important patient characteristics such as age, 
diagnosis-based comorbidity index and type of treatment. Diagnosis-based comorbidity indices 
can be considered as proxies for patient health status—evidently, the higher the index, the poorer 
the health status. Vast empirical evidence shows that these indices are good predictors of 
mortality and of adverse events, such as amputation, hospitalisation, longer inpatient stay, and re-
admission to hospital (Charlson et al. 1987, Lix et al. 2013, Quail et al. 2011, Quan et al. 2011, 
Rochon et al. 1996). This study uses three diagnosis-based comorbidity measures, including the 
Charlson comorbidity index (Charlson et al. 1987), the Quan-modified Charlson comorbidity 
index (Quan et al. 2011), and the Elixhauser measure (Elixhauser et al. 1998) identified by 
Sharabiani et al (2012) as the most common. ICD-10 codes are employed to identify which of the 
comorbid conditions apply to the patients in the sample. To control for potential bias in ICD-10 
coding, this study also measures comorbidity by counting the number of third-level ATC codes4 
on which the patient received at least one prescription semi-annually.  
 
 
Results 
 
The final sample includes 794 general practitioners and 318 specialists in endocrinology who 
shared care for 31,070 diabetic patients. Over the two-year sample period general practitioners 
issued 509,281 specialist medication prescriptions for antidiabetic agents and wrote an additional 
3,575,726 prescriptions. A typical general practitioner treated 39 diabetic patients and wrote 1060 
prescriptions for antidiabetic agents—14 prescriptions per patient per year. On average, a general 
practitioner coordinated care with eight specialists.  
 
Table 1 compares characteristics of patients treated by general practitioners who built up strong 
collaborative relationships with specialists with those of patients treated by general practitioners 
who are connected to specialists with weak, fragmented ties. Table 1 shows mean values or 
proportions, as appropriate. Patients treated in strong collaborative relationships have more 
diabetes-related complications, receive less prescription for antidiabetic agents, and consult more 
frequently with their general practitioners. The two cohorts do not differ significantly in age, 
                                                          
4 The third level of an ATC code includes the main anatomical group (first level, one letter), the main therapeutic 
group (second level, two digits), and the therapeutic/pharmacological subgroup (third level, one letter), but excludes 
the chemical/therapeutic/pharmacological subgroup (fourth level, one letter) and the chemical substance (fifth level, 
two digits) (WHO 2003). 
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gender mix, type of therapy, number of prescriptions in total, or frequency of consultations with 
specialists. Two comorbidity measures (Quan-modified Charlson comorbidity index and ATC-
based comorbidity count) indicate that patients in both cohorts have the same number of 
comorbidities. The other two comorbidity measures (Charlson comorbidity index and 
Elixhhauser measure) signal that strong, collaborative structures is coupled with less 
comorbidities diagnosed and treated.  
 
Table 1 General practitioners (GPs) with strong collaborative structures vs weak, fragmented 
structure: patient characteristics 
Patient characteristics 
GPs with strong 
collaborative ties 
(uppermost 
decile) 
GPs with 
weak, 
fragmented 
ties (lowest 
decile) 
p-value  
Gender (%) 
male 52.59 52.89 
0.8140 
female 47.41 47.11 
Average age 65.48 65.68 0.3293 
Diabetes (%, based on ICD-10 codes) 
with complications 61.24 56.33 
0.0000 
without complications 38.76 43.67 
Treatment (%, based on third-level ATC codes) 
insulin based 71.18 71.26 
0.9409 
non-insulin based 28.82 28.74 
Comorbidity indices 
Charlson comorbidity index 
Quan-modified Charlson comorbidity index 
Elixhauser measure 
ATC-based comorbidity count 
0.88 
0.59 
1.92 
7.86 
0.94 
0.58 
2.01 
8.02 
0.0264 
0.5183 
0.0058 
0.1749 
Prescriptions per patient 
for all agents 127.41 130.05 0.2679 
for antidiabetic agents 25.28 27.27 0.0000 
Consultations per patient 
with the general practitioner, for all 
prescriptions 22.55 21.53 0.0023 
with the specialist, for therapy-initiating 
prescriptions 2.33 2.471 0.0187 
 
The bivariate analysis shows that the type of collaborative structure is associated with 
prescription drug costs—they are 5.88% lower for patients treated by general practitioners who 
build up strong collaborative relationships with specialists than for patients treated by general 
practitioners who are connected to specialists with weak, fragmented ties (Table 2).  
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Table 2 Bivariate analysis for general practitioners with strong collaborative structures vs weak, 
fragmented structure 
Outcome measure 
GPs with strong 
collaborative ties 
(uppermost decile, 
mean value) 
GPs with weak, 
fragmented ties 
(lowest decile, mean 
value) 
p-
value  
Prescription drug costs (based on 
retail prices as of January 2010; 
thousand Hungarian Forint) 
586.58 623.22 0.0000     
 
In Hungary, access to secondary care is regulated, free provider choice is restricted to the primary 
care level. One might argue that in small settlements, where the supply of specialists is smaller, 
general practitioners naturally build up strong collaborative relationships. Using settlement size 
as moderator variable, our results remained practically unchanged—prescription drug costs were 
lower in the three subsamples split by settlement size. 
 
The finding that general practitioners with strong collaborative structure involve lower pharmacy 
costs is based on a bivariate analysis that does not account for confounding variables. To address 
the issue of confounding, a multivariate regression analysis is performed—the variation in 
pharmacy costs is explained by the type of collaborative structure, the Quan-modified Charlson 
comorbidity index, and potentially important patient characteristics (Table 3). 
 
Table 3 Determinants of prescription drug costs: multivariate regression analysis on type of 
collaborative structures and patient characteristics* 
 Independent variables  
Standardized 
Coefficients Sig. 
Beta 
General practitioner’s 
collaboration with specialists 
Strong, collaborative structure  (0/1) -0.020  0.001 
Weak, fragmented structure (0/1)  0.014 0.001 
Quan-modified Charlson comorbidity index -0.011 0.013 
Patients' age 0.164 0.000 
Patients' age squared -0.261 0.000 
Patients’ gender (0-female, 1-male) -0.024 0.000 
Diabetes without complications/ with complications (0/1, based on ICD-10 
codes) 
0.015 0.001 
Treatment method (0 - non-insulin based, 1-insulin based)  0.196 0.000 
Prescriptions per patient for all agents 0.581 0.000 
Consultations per patient (with the specialist for therapy-initiating 
prescriptions) 
0.062 0.000 
R2=.408 
* Variables excluded from the multivariate regression analysis due to high correlation (<0.6): Charlson 
comorbidity index, Elixhauser measure, ATC-based comorbidity count, Prescriptions per patient for antidiabetic 
agents, Consultations per patient with the general practitioner.  
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Most importantly, the multivariate analysis confirms that the type of collaborative structure is a 
statistically significant determinant of prescription drug costs. In addition to the type of 
collaborative structures, both the treatment method and the presence of diabetes complications is 
an important determinant of prescription drug costs—patients treated by the generally more 
expensive insulin and patients who have diabetes complications involve significantly higher 
prescription drug costs. 
 
 
Discussion 
 
Both bivariate and multivariate analysis confirm that prescription drug costs for patients treated 
by general practitioners who build up strong collaborative relationships with specialists are 
significantly lower than for patients treated by general practitioners characterized by fragmented 
collaborative structures, a major benefit for the society as a whole.  
 
The significant difference in prescription drug costs is neither related to the total number of 
prescriptions patients receive, nor to the number of comorbidities diagnosed and treated, as 
measured by the Quan-modified Charlson comorbidity index or the ATC-based comorbidity 
count (Table 1). The difference cannot be explained by the severity of the diabetes as well, as our 
data suggests that patients treated in strong collaborative relationships tend to have more 
diabetes-related complications (Table 1). 
 
The finding that collaborative structures affect prescription drug cost is in line with previous 
literature reporting that better care coordination is associated with lower health utilization, 
including lower hospitalization and fewer emergency visits (Barnett et al. 2012, Pollack et al. 
2013, Uddin et al. 2011). For example, the systematic review of van Walraven et al. (2010) finds 
that better care coordination is associated with lower health utilization, including lower 
hospitalization and fewer emergency visits. The recent literature using the newly developed 
measure of care coordination finds evidence for the significant association between the level of 
care coordination and cost of care as well (Barnett et al. 2012, Pollack et al. 2013, 2014, Uddin et 
al. 2011). This article finds empirical evidence for this association on system-level for primary 
care providers—association never tested in the literature before. Previous studies either assessed 
the results of patient care coordination on a small scale (Bosch et al. 2009, Lemieux-Charles and 
McGuire 2006), or did not focus on primary care providers (Barnett et al. 2012, Pollack et al. 
2013, Uddin et al. 2011). 
 
This study might bear important policy implications with regards to care fragmentation—general 
practitioners may struggle to coordinate care, if they should collaborate with more specialists as a 
result, and prescription drug costs would be higher. If future research shows that total healthcare 
costs are indeed lower for patients treated in strong collaborative structures when numerous other 
specialties are considered as well, then healthcare strategists need to advocate a healthcare system 
with lower care fragmentation. Offering completely free choice to secondary care providers, 
advocated in several developed countries, such as the United Kingdom and the Netherlands 
(Bevan and Van De Ven 2010), may increase care fragmentation by forcing general practitioners 
to collaborate with more providers. In counties with universal health coverage, lower care 
fragmentation might be achieved through offering patients limited rather than unrestricted choice. 
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In countries without universal health coverage, such as the US, healthcare insures should follow a 
narrow provider network strategy which would allow them to offer lower premiums. Lower care 
fragmentation, coupled with enhanced medical education and technical infrastructure might 
benefit patients, by savings on travel times and costs, and the wider society, by savings on 
healthcare costs. 
 
This study has a number of limitations worth future further exploration. First, sampling bias 
might be present due to general practitioners supplying prescription data voluntarily and 
excluding remote or recently opened/closed practices during data cleaning. Second, prescription 
drug costs are just one element of the total patient care costs—additional analyses are necessary 
to examine other elements, such as outpatient and inpatient costs, as main outcome measures. 
Third, the specialists analyzed in this article were all endocrinologists practicing in Hungary—
future research needs to investigate results for validity with other specialties and countries. 
Fourth, diagnoses data entering into the comorbidity scoring is incomplete. If a diagnosis made 
by a specialist did not imply a further need for prescription by general practitioners, then the 
diagnosis was not listed among the patients’ comorbid conditions. Fifth, lower prescription drug 
cost is only one aspects when the functioning of shared-care schemes is to be evaluated. Several 
other factors to be considered include, for example, potential improvement in clinical outcomes; 
the degree of participation by patients and healthcare teams; the long-term continuity of care; 
therapeutic adherence; and the level and ease of communication between specialists and general 
practitioners. Finally, we were unable to assess whether patients treated in stronger general 
practitioner–specialist connections perceived better care—or were more satisfied—than others.  
 
 
Summary 
 
In chronic illness care, many patient outcomes may only be achieved if the clinical activities of 
different health professionals—such as general practitioners and specialists—are intentionally 
coordinated. Improving patient care coordination has become a key focus in healthcare reform 
and a national priority in numerous countries. However, assessing patient care coordination is as 
challenging as achieving it. This study took a leap forward in assessing the function of primary 
care at system level. In particular, a provider-level care coordination measure was developed, and 
the possible impact of different kinds of collaborative structures on prescription drug costs was 
measured.  We found that prescription drug costs for patients treated by general practitioners who 
build up strong collaborative relationships with specialists are significantly lower than for 
patients treated by general practitioners characterized by fragmented collaborative structures. 
Overall drug expenditure may thus be reduced by lowering patient care fragmentation through 
channeling a general practitioner’s patients to a small number of specialists. If future system-
level studies in other settings confirm that total healthcare costs are indeed lower for patients 
treated in strong collaborative structures, then healthcare policy strategists need to advocate a 
healthcare system with lower care fragmentation on the interface of primary and secondary care. 
Regulating access to secondary care might result in significant cost savings. 
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